Susanne Kirchner

Ms. Susanne Kirchner

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SKSusanne Kirchner
Susanne Kirchner
ALAnna-Lena Leistner
Anna-Lena Leistner
PGPeter Gödtel
Peter Gödtel
ASAngelika Seliwjorstow
Angelika Seliwjorstow
SWSven Weber
Sven Weber
ZPZbigniew L. Pianowski
Zbigniew L. Pianowski
Molecular photoswitches transform light energy into reversible structural changes. Their combination with known pharmacophores often allows for photomodulation of the biological activity. The effort to apply such compounds in photopharmacology as light-activated pro-drugs is, however, hampered by serious activity reduction upon pharmacophore modifications, or limited biostability. Here we report that a potent antimitotic agent plinabulin and its derivatives demonstrate up to 56-fold reversible activity photomodulation. Alternatively, irreversible photoactivation with cyan light can enhance the cytotoxicity up to three orders of magnitude—all without compromising the original activity level, as the original pharmacophore structure is unchanged. This occurs due to the presence of a peptide-derived photoswitchable motif hemipiperazine inside the plinabulin scaffold. Furthermore, we systematically describe photochromism of these thermally stable and biocompatible hemipiperazines, as well as a photoswitchable fluorophore derived from plinabulin. The latter may further expand the applicability of hemipiperazine photochromism towards super-resolution microscopy.

Verified
Journal Article
Open access
PDF file
SKSusanne Kirchner
Susanne Kirchner
ZPZbigniew L. Pianowski
Zbigniew L. Pianowski
Antimitotic agents such as the clinically approved vinca alkaloids, taxanes and epothilone can arrest cell growth during interphase and are therefore among the most important drugs available for treating cancer. These agents suppress microtubule dynamics and thus interfere with intracellular transport, inhibit cell proliferation and promote cell death. Because these drugs target biological processes that are essential to all cells, they face an additional challenge when compared to most other drug classes. General toxicity can limit the applicable dose and therefore reduce therapeutic benefits. Photopharmacology aims to avoid these side-effects by introducing compounds that can be applied globally to cells in their inactive form, then be selectively induced to bioactivity in targeted cells or tissue during a defined time window. This review discusses photoswitchable analogues of antimitotic agents that have been developed by combining different photoswitchable motifs with microtubule-stabilizing or microtubule-destabilizing agents.

15 March 2024 in Macromolecular Materials and Engineering
Verified
Journal Article
Open access
ASAngelika Seliwjorstow
Angelika Seliwjorstow
MBMarius Bach
Marius Bach
SKSusanne Kirchner
Susanne Kirchner
SPSarah Palloks
Sarah Palloks
ZPZbigniew L. Pianowski
Zbigniew L. Pianowski
Amphiphilic cyclic dipeptides are efficient supramolecular hydrogelators. They can be combined with molecular photoswitches to produce light‐responsive soft materials, which can be applied in controlled drug delivery. Here it is reported that an arginine‐containing cyclic dipeptide decorated with ortho‐fluorinated azobenzene forms hydrogels under physiological conditions that can be reversibly liquefied upon exposure to visible light frequencies (green and violet, respectively). The addition of sodium alginate results in composite supramolecular hydrogels with increased gelating capacity supported with Coulombic interactions, which also reversibly dissipate upon irradiation.